Related Experiment Video
Updated: Feb 6, 2026

Author Spotlight: Exploring Behavioral Pathways Through Cross-Species Insights in Foraging and Communication
Published on: November 17, 2023
[Search for the T790M mutation: The need to persevere]
H Bourien1, A Lespagnol2, A Prigent3
1Centre Eugène-Marquis, avenue de la Bataille-Flandres-Dunkerque, 35000 Rennes, France.
Abstract:
In cases of advanced EGFR mutation-positive non-small cell lung cancer, first or second generation EGFR-tyrosine kinase inhibitors (TKI-EGFR 1G or TKI-EGFR 2G) are recommended as first line treatment. Inexorably, progressive disease occurs and, in 50-60% of the cases, is secondary to a T790M resistant mutation. The prescription of osimertinib (TKI-EGFR3G) in second line is dependent on identification of the T790M mutation. We report 7 cases in which the identification of the T790M mutation required repeated analyses of cell free DNA and/or biopsies over a period of time. In some cases, a positive result was obtained a long time after progressive disease had been diagnosed during treatment with first or second generation EGFR-TKI. We discuss here the different modalities of screening for the T790M mutation and we encourage persevering in this search when no alternative mechanism of resistance has been identified.
Insights
For advanced EGFR-positive lung cancer, T790M mutation testing is crucial for guiding treatment with third-generation EGFR-TKIs. Persistent screening for this resistance mutation is recommended, even after initial negative results.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- First- or second-generation EGFR-tyrosine kinase inhibitors (TKIs) are standard first-line treatments for advanced EGFR mutation-positive non-small cell lung cancer.
- Disease progression is common, with 50-60% of cases developing resistance due to the T790M mutation.
Observation:
- Osimertinib (a third-generation EGFR-TKI) is a second-line treatment option, but its use requires T790M mutation identification.
- This report details 7 cases where identifying the T790M mutation necessitated repeated cell-free DNA and/or biopsy analyses over time.
- In some instances, a positive T790M result was confirmed significantly after disease progression was noted during first- or second-generation EGFR-TKI therapy.
Findings:
- Repeated testing for the T790M resistance mutation can yield positive results even after initial negative findings.
- The timing of T790M mutation detection can be delayed, occurring long after disease progression is clinically evident.
Implications:
- This highlights the importance of persistent T790M mutation screening in non-small cell lung cancer patients experiencing progression on EGFR-TKIs.
- Exploring various screening methods for the T790M mutation is encouraged.
- Perseverance in seeking the T790M mutation is advised when no other resistance mechanisms are identified.
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Viral Mutations
Mutation, Gene Flow, and Genetic Drift
Mutations in Microorganisms
Point and Frameshift Mutations

